Safety and Effectiveness of Nintedanib in Korean Patients

Study in Patients With COPD

NCT00215449 ·Status: COMPLETED ·Phase: PHASE3

A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251

NCT02449018 ·Status: COMPLETED ·Phase: PHASE2

An Expanded Access Program to Provide Nintedanib to Patients With Non-IPF ILD Who Have no Alternative Treatment Possibilities

NCT03843892 ·Status: APPROVED_FOR_MARKETING

Phase II Study to Evaluate the Cardiac Safety of 2 Doses of CHF5993 Both Combined With CHF1535 BID Versus CHF1535 BID in Patients With Moderate to Severe COPD

NCT01584505 ·Status: COMPLETED ·Phase: PHASE2

Safety and Tolerability of Multiple Inhaled NVA237 Doses in Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT00545311 ·Status: COMPLETED ·Phase: PHASE1

INCHANGE - Nintedanib for Changes in Cough and Dyspnea in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease With a Progressive Phenotype in Everyday Clinical Practice: a Real-world Evaluation

NCT05151640 ·Status: COMPLETED

Safety Study to Evaluate MN-221 in Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT01551316 ·Status: COMPLETED ·Phase: PHASE1

Safety and Efficacy Study of Treatment With Single Doses of CHF 4226 pMDI in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00782535 ·Status: COMPLETED ·Phase: PHASE2

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of GSK2256294 in Healthy Volunteers, and Single and Repeat Doses of GSK2256294 in Adult Male Moderately Obese Smokers

NCT01762774 ·Status: COMPLETED ·Phase: PHASE1

An Expanded Access Program in Belgium to Provide Nintedanib to People With Lung Diseases Called Non-IPF ILDs Who Have no Alternative Treatment Options

NCT04739150 ·Status: NO_LONGER_AVAILABLE

Efficacy and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT01119950 ·Status: COMPLETED ·Phase: PHASE2

Study in Patients With COPD

NCT00215384 ·Status: COMPLETED ·Phase: PHASE2

Revefenacin in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease(COPD)

NCT05046795 ·Status: COMPLETED ·Phase: PHASE3

Long Term Safety Study of NVA237 vs QAB149 in COPD Patients

NCT01697696 ·Status: COMPLETED ·Phase: PHASE3

Evaluate the Safety of MN-221 in Subjects With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT01013142 ·Status: COMPLETED ·Phase: PHASE1

A Phase 1 Study To Evaluate The Safety And Tolerability Of Different Doses Of PF-03526299 In Healthy Adult Volunteers

NCT00990756 ·Status: COMPLETED ·Phase: PHASE1

A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation

NCT01682863 ·Status: COMPLETED ·Phase: PHASE3

A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD

NCT04542057 ·Status: COMPLETED ·Phase: PHASE3

To Assess the Excretion Balance and Pharmacokinetics of a Single Oral Dose of [14C]GW856553 in Healthy Adult Males

NCT00599612 ·Status: COMPLETED ·Phase: PHASE1

Diarrheal Adverse Events in Caucasian Patients With Idiopathic Pulmonary Fibrosis Undergoing Treatment With Nintedanib

NCT06714812 ·Status: ACTIVE_NOT_RECRUITING

Randomized, Double-blind, Placebo-controlled, Multicenter, Cross-over Study to Assess the Effects of a 3 Week Therapy Each With QVA149 Versus Placebo on Pulmonary Function and Average Physical Activity Levels in Patients With COPD.

NCT01996319 ·Status: COMPLETED ·Phase: PHASE3

Evaluate the Safety Profile of BGF MDI in Chinese Patients With COPD in Routine Clinical Practice

NCT04536402 ·Status: COMPLETED

A Phase II, Study To Evaluate The Efficacy And Safety Of PH-797804 In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD).

NCT00559910 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate the Efficacy and Safety of Ensifentrine for 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT05743075 ·Status: COMPLETED ·Phase: PHASE3

Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT01266135 ·Status: TERMINATED ·Phase: PHASE2